Stockscreener 앱 받기
153.57
1.88%
-2.94
시간 외 거래:
153.71
0.14
+0.09%
전일 마감가:
$156.51
열려 있는:
$154.73
하루 거래량:
6.18M
Relative Volume:
0.98
시가총액:
$190.42B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
20.90
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
+0.02%
1개월 성능:
+2.00%
6개월 성능:
+15.21%
1년 성능:
+23.77%
1일 변동 폭
$151.71
$155.42
1주일 범위
$151.71
$157.57
52주 변동 폭
$114.02
$160.51
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
153.57 | 190.42B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-07-06 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2026-05-20 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
BofA raises Gilead Sciences stock price target on positive trial data - Investing.com
15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC - MarketBeat
How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals - Yahoo Finance
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success - Benzinga
Gilead Sciences, Inc. (GILD) stock price, news, quote and history - Yahoo Finance UK
What Has Changed About Owning Gilead Stock? - Trefis
Gilead Sciences (GILD) Reports Promising Mid-Stage Trial Results for Emvistegrast in Ulcerative Colitis - GuruFocus
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy - Zacks Investment Research
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy - Yahoo Finance
Gilead's pill succeeds in mid-stage bowel disease trial - Reuters
Gilead bowel drug hits mid-stage trial win (GILD:NASDAQ) - Seeking Alpha
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - BioSpace
Gilead to present HIV and antiviral research at IDWeek 2026 - Investing.com
Gilead Sciences, Inc. (GISD.XC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - Business Wire
43 ETFs Add to Gilead Sciences (GILD) on Thursday - Yahoo Finance
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds - STAT
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? - The Motley Fool
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc. - MarketBeat
Under a trading plan, Gilead Sciences (GILD) CFO sells 3,000 shares at $156.22 each. - Stock Titan
Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC - MarketBeat
Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation? - Kalkine Media
Gilead Sciences, Inc. $GILD Stock Sold by Assenagon Asset Management S.A. - MarketBeat
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Yahoo Finance
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Zacks Investment Research
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
Gilead Sciences Inc Stock (GILD) Moved Up by 3.67% on Oct 15: Key Drivers Unveiled - TradingKey
Gilead Sciences (NASDAQ:GILD) Hits New 52-Week HighHere's What Happened - MarketBeat
Gilead Sciences stock hits all-time high at 157.32 USD - Investing.com
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership? - Yahoo Finance
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers - BioSpace
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal - Reuters
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Business Wire
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Earnings Preview: What to Expect From Gilead Sciences’ Report - Barchart.com
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says - Yahoo Finance
Can Gilead (GILD) Stock Continue Rising in 2027? - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
BofA raises Gilead Sciences stock price target on growth outlook By Investing.com - Investing.com India
RBC raised target for Gilead Sciences stock to USD 126.00 - ad-hoc-news.de
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Oct 15 '26 |
Sale |
156.22 |
3,000 |
468,660 |
113,684 |
| JOHANNA MERCIER | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| ANDREW DICKINSON | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Oct 01 '26 |
Sale |
147.90 |
15,000 |
2,218,508 |
566,683 |
| ANDREW DICKINSON | Officer |
Sep 15 '26 |
Proposed Sale |
145.29 |
3,000 |
435,870 |
0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| JOHANNA MERCIER | Officer |
Sep 15 '26 |
Proposed Sale |
144.22 |
3,000 |
432,646 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Sep 01 '26 |
Sale |
148.64 |
15,000 |
2,229,592 |
577,133 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
0.74%
자본화:
|
볼륨(24시간):